Avacopan in Participants With ANCA-associated Vasculitis

Short Title: AMG- 569

Enrollment Status: Recruiting

NCT #: NCT06072482

Specialty Area: Rheumatology

Condition Studied: Antineutrophil Cytoplasmic Antibodies (ANCA)- Associated Vasculitis

Age Groups: Adult; Older Adult

Phase: IV

Study Information

Summary / Purpose

To evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Newly diagnosed or relapse of granulomatosis with polyangiitis or microscopic polyangiitis, consistent with Chapel-Hill Consensus Conference definitions (Jennette et al, 2013), where induction treatment with cyclophosphamide or rituximab is needed

What's Involved

Participation in the study will include:

Medication given orally twice a day for 5 years
Attending planned visits during the treatment period and follow-up
Electrocardiogram (ECG) to measure the electrical activity of your heart
Chest x-ray
Serum or urine pregnancy test (for women who can have children)
Blood and urine samples

Principal Investigator

Kennedy Ukadike, MD

Rheumatology

A Member of

(775) 982–5000

Renown Rheumatology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06072482

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews